Sana Biotechnology announces departure of Sunil Agarwal as EVP, Head of Development and CMO

Sana Biotechnology, Inc.

Separation effective April 28, 2023; Sunil Agarwal to provide transition services under a Transition Agreement.
Severance of $560,523 (9 months base salary plus pro-rata bonus) plus COBRA coverage for up to 9 months.
Acceleration of 89,377 unvested stock options; exercise period extended to December 31, 2023.
Consulting Agreement at $256/hour, effective April 29, 2023, ending May 12 or extended to May 26, 2023.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sunil Agarwal

Executive Vice President, Head of Development, and Chief Medical Officer

SANA · Sana Biotechnology, Inc.

Effective: 2023-04-28
Filed: April 28, 2023, 7:59 PM ET

Sana Biotechnology, Inc. (the “Company”) previously filed a Current Report on Form 8-K disclosing the resignation of Sunil Agarwal, M.D. as the Company’s Executive Vice President, Head of Development, and Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sunil Agarwal resigned as Executive Vice President, Head of Development, and Chief Medical Officer at Sana Biotechnology, Inc..

Action: resigned
Role: Executive Vice President, Head of Development, and Chief Medical Officer

Exact text from the filing

Sana Biotechnology, Inc. (the “Company”) previously filed a Current Report on Form 8-K disclosing the resignation of Sunil Agarwal, M.D. as the Company’s Executive Vice President, Head of Development, and Chief Medical Officer.

View on SEC.gov

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-23-006600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.